3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Small Cell Lung Carcinoma
46
Lymphoma, Large B-Cell, Diffuse
26
Precursor Cell Lymphoblastic Leukemia-Lymphoma
24
Lung Neoplasms
21
Leukemia, Myeloid, Acute
20
Burkitt Lymphoma
18
Hodgkin Disease
15
Recurrence
14
Lymphoma, Non-Hodgkin
14
Lymphoma
14
Carcinoma, Non-Small-Cell Lung
11
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
10
Neuroblastoma
10
Lymphoma, Mantle-Cell
10
Lymphoma, B-Cell
10
Leukemia
10
Medulloblastoma
8
Neoplasms, Germ Cell and Embryonal
7
Neoplasms
7
Lymphoma, Follicular
7
Multiple Myeloma
6
Lymphoma, T-Cell
6
Brain Neoplasms
6
Sarcoma, Ewing
5
Retinoblastoma
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Immunoblastic Lymphadenopathy
5
Ependymoma
5
Sarcoma
4
Rhabdomyosarcoma
4
Interventions
Magnetic Resonance Spectroscopy
7
X-Rays
6
Specimen Handling
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
5
Biopsy
5
ulixertinib
2
trametinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
dabrafenib
2
LY3023414
2
olaparib
1
etoposide phosphate
1
cobimetinib
1
Vemurafenib
1
Sirolimus
1
Pharmacogenomic Variants
1
Lenalidomide
1
Genetic Testing
1
Etoposide
1
Cyclophosphamide
1
Celecoxib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Histiocytosis, Langerhans-Cell
×
Etoposide
×
1 year
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled